Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Biogen Inc. | SPINRAZA (Nusinersen) - (ASCEND) | Spinal muscular atrophy (SMA) | Phase 3 | Trial Planned | Intrathecal | Genetic Disorder |
| Biogen Inc. | Natalizumab - (NOVA) | Multiple sclerosis (MS) | Phase 3 | Data Released | Intravenous | Neurology |
| Biogen Inc. | Felzartamab - (TRANSCEND) | Antibody-mediated rejection (AMR) in kidney transplant recipients | Phase 3 | Ongoing | Intravenous | Immunosuppressant |
| Biogen Inc. | Felzartamab - (PREVAIL) | IgA nephropathy (IgAN) | Phase 3 | Ongoing | Intravenous | Immunology |
| Biogen Inc. | Felzartamab | Primary membranous nephropathy (PMN) | Phase 3 | Trial Completed | Intravenous | Immunology |
| Biogen Inc. | Felzartamab (MOR202) - (PROMINENT) | Membranous nephropathy (MN) | Phase 3 | Enrollment Initiation | Intravenous | Immunology |
| Biogen Inc. | Bardoxolone - (FALCON) | Chronic Kidney Disease | Phase 3 | Trial Discontinued | Oral | N/A |
| Biogen Inc. | Bardoxolone methyl - CATALYST | Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH | Phase 3 | Trial Discontinued | Oral | Cardiology |
